Risk factors

What each company says could go wrong in its 10-K, and what changed since last year: the risks added, dropped and rewritten.

7,691 annual reports · 4,011 companies

Readings are automated and can be wrong; check the filing for the exact wording.

Older filings

Page 469 of 641 · 7,691 filings

  • TScan Therapeutics (TCRX) FY2024 10-K risk factors
    121 risks

    TScan faces heavy financial risks with sustained operating losses and reliance on external financing, including a $52.5 million loan facility with Silicon Valley Bank.

    Filed Mar 05, 2025
  • First Financial (THFF) FY2024 10-K risk factors
    43 risks

    First Financial Corp faces concentrated geographic risks across multiple states and heavy exposure to commercial real estate loans. The bank is sensitive to interest rate fluctuations, inflation, and regulatory changes under the new presidential administration. Integration risks from the SimplyBank acquisition and cybersecurity threats also feature prominently.

    Filed Mar 05, 2025
  • TriplePoint Venture Growth BDC (TPVG) FY2024 10-K risk factors
    76 risks

    The company relies heavily on key executive officers and external advisors for its venture growth investment strategy. Portfolio investments are concentrated in volatile technology and high-growth sectors with limited diversification. The business depends on maintaining BDC and RIC tax status while managing debt leverage and credit facility risks.

    Filed Mar 05, 2025
  • Westwood Holdings Group (WHG) FY2024 10-K risk factors
    27 risks

    Revenues depend heavily on fluctuating AUM and AUA market values, alongside fee pressure from passive strategies.

    Filed Mar 05, 2025
  • Westlake Chemical Partners (WLKP) FY2024 10-K risk factors
    49 risks

    Company risk profile is dominated by operational and financial dependence on parent Westlake, variable interest debt, and fixed-margin ethylene pricing structures.

    Filed Mar 05, 2025
  • Zymeworks (ZYME) FY2024 10-K risk factors
    68 risks

    Zymeworks relies heavily on partner Jazz for commercializing Ziihera and advancing zanidatamab. The company faces high clinical trial, regulatory, and patent protection risks across its early-stage pipeline.

    Filed Mar 05, 2025
  • Flutter Entertainment (FLUT) FY2024 10-K risk factors
    71 risks

    Regulatory, tax and licensing changes across major markets could restrict products, increase costs or threaten operating permissions.

    Filed Mar 04, 2025
  • Hagerty (HGTY) FY2024 10-K risk factors
    59 risks

    Insurance underwriting, claims, reinsurance, carrier relationships, and regulation dominate Hagerty’s risk profile.

    Filed Mar 04, 2025
  • Ascent Industries (ACNT) FY2024 10-K risk factors
    23 risks

    Ascent Industries Co. faces risks heavily concentrated on manufacturing hazards, raw material volatility, and cyclical demand in its Tubular Products and Specialty Chemicals segments.

    Filed Mar 04, 2025
  • Adial Pharmaceuticals (ADIL) FY2024 10-K risk factors
    64 risks

    Clinical stage biotechnology company dependent on lead product candidate AD04 for treating alcohol use disorder.

    Filed Mar 04, 2025
  • Bank of Hawaii (BOH) FY2024 10-K risk factors
    32 risks

    Hawaiʻi, Guam and Pacific Island concentration makes local economies, real estate and defense spending central to performance.

    Filed Mar 04, 2025
  • Custom Truck One Source (CTOS) FY2024 10-K risk factors
    24 risks

    Heavy reliance on debt leverage with $1,547.7 million total indebtedness dominated the risk section. Exposure to vehicle and equipment supply chain constraints and steel costs is prominent. Controlling ownership by Platinum creates significant governance concentration risks.

    Filed Mar 04, 2025

Companies covered

4,011 companies

371 more under A